EGFR and non-small cell lung carcinoma: Non-small cell lung cancer (NSCLC) associated with epidermal growth factor receptor (EGFR) mutations has experienced notable therapeutic advancements; however, exon 20 insertion mutations continue to pose a significant challenge, demonstrating resistance to conventional EGFR inhibitors.